Skip to main content
Erschienen in: Neurological Sciences 3/2016

01.03.2016 | Original Article

Assessment of voice and speech symptoms in early Parkinson’s disease by the Robertson dysarthria profile

verfasst von: Giovanni Defazio, Marta Guerrieri, Daniele Liuzzi, Angelo Fabio Gigante, Vincenzo di Nicola

Erschienen in: Neurological Sciences | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Changes in voice and speech are thought to involve 75–90 % of people with PD, but the impact of PD progression on voice/speech parameters is not well defined. In this study, we assessed voice/speech symptoms in 48 parkinsonian patients staging <3 on the modified Hoehn and Yahr scale and 37 healthy subjects using the Robertson dysarthria profile (a clinical–perceptual method exploring all components potentially involved in speech difficulties), the Voice handicap index (a validated measure of the impact of voice symptoms on quality of life) and the speech evaluation parameter contained in the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III). Accuracy and metric properties of the Robertson dysarthria profile were also measured. On Robertson dysarthria profile, all parkinsonian patients yielded lower scores than healthy control subjects. Differently, the Voice Handicap Index and the speech evaluation parameter contained in the UPDRS-III could detect speech/voice disturbances in 10 and 75 % of PD patients, respectively. Validation procedure in Parkinson’s disease patients showed that the Robertson dysarthria profile has acceptable reliability, satisfactory internal consistency and scaling assumptions, lack of floor and ceiling effects, and partial correlations with UPDRS-III and Voice Handicap Index. We concluded that speech/voice disturbances are widely identified by the Robertson dysarthria profile in early parkinsonian patients, even when the disturbances do not carry a significant level of disability. Robertson dysarthria profile may be a valuable tool to detect speech/voice disturbances in Parkinson’s disease.
Literatur
1.
Zurück zum Zitat Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed
2.
Zurück zum Zitat Bohnen NI, Cham R (2006) Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin Geriatr Med 22:797–812CrossRefPubMed Bohnen NI, Cham R (2006) Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin Geriatr Med 22:797–812CrossRefPubMed
3.
Zurück zum Zitat Darley FL, Aronson AE, Brown JR (1969) Clusters of deviant speech dimensions in he dysarthrias. J Speech Lang Hear Res 12:462CrossRef Darley FL, Aronson AE, Brown JR (1969) Clusters of deviant speech dimensions in he dysarthrias. J Speech Lang Hear Res 12:462CrossRef
4.
Zurück zum Zitat Darley FL, Aronson AE, Brown JR (1969) Differential diagnostic patterns of dysarthria. J Speech Hear Res 12:246–269CrossRefPubMed Darley FL, Aronson AE, Brown JR (1969) Differential diagnostic patterns of dysarthria. J Speech Hear Res 12:246–269CrossRefPubMed
5.
Zurück zum Zitat Sapir S, Ramig L, Fox C (2008) Speech and swallowing disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg 16:205–210CrossRefPubMed Sapir S, Ramig L, Fox C (2008) Speech and swallowing disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg 16:205–210CrossRefPubMed
6.
Zurück zum Zitat Ramig LO, Fox C, Sapir S (2008) Speech treatment for Parkinson’s disease. Expert Rev Neurother 8:297–309CrossRefPubMed Ramig LO, Fox C, Sapir S (2008) Speech treatment for Parkinson’s disease. Expert Rev Neurother 8:297–309CrossRefPubMed
7.
Zurück zum Zitat Ho AK, Iansek HR, Marigliani C, Bradshawa JL, Gates S (1999) Speech impairment in a large sample of patients with Parkinson’s disease. Behav Neurol 11:131–137CrossRefPubMed Ho AK, Iansek HR, Marigliani C, Bradshawa JL, Gates S (1999) Speech impairment in a large sample of patients with Parkinson’s disease. Behav Neurol 11:131–137CrossRefPubMed
8.
Zurück zum Zitat Logemann JA, Fisher HB, Boshes B, Blonsky ER (1978) Frequency and co-occurrence of vocal tract dysfunction in the speech of a large sample of parkinsonian patiens. J Speech Heart Disord 43:47–57CrossRef Logemann JA, Fisher HB, Boshes B, Blonsky ER (1978) Frequency and co-occurrence of vocal tract dysfunction in the speech of a large sample of parkinsonian patiens. J Speech Heart Disord 43:47–57CrossRef
9.
Zurück zum Zitat Muller J, Wenning GK, Verny M, McKee A, Chaudury KR, Jellinger K, Poewe W, Litvan I (2001) Progression of Dysarthria and dysphagia in post-mortem confirmed parkinsonian disorders. Arch Neurol 58:259–264CrossRefPubMed Muller J, Wenning GK, Verny M, McKee A, Chaudury KR, Jellinger K, Poewe W, Litvan I (2001) Progression of Dysarthria and dysphagia in post-mortem confirmed parkinsonian disorders. Arch Neurol 58:259–264CrossRefPubMed
10.
Zurück zum Zitat Rusz J, Cmejla R, Ruzickova H, Ruzicka E (2011) Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. J Acoust Soc Am 129:350–367CrossRefPubMed Rusz J, Cmejla R, Ruzickova H, Ruzicka E (2011) Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. J Acoust Soc Am 129:350–367CrossRefPubMed
11.
Zurück zum Zitat Stewart C, Winfield L, Hunt A, Bressman SB, Fahn S, Blitzer A, Brin MF (1995) Speech dysfunction in early Parkinson’s disease. Mov Disord 10:562–565CrossRefPubMed Stewart C, Winfield L, Hunt A, Bressman SB, Fahn S, Blitzer A, Brin MF (1995) Speech dysfunction in early Parkinson’s disease. Mov Disord 10:562–565CrossRefPubMed
12.
Zurück zum Zitat Skodda S, Rinsche H, Schlegel U (2009) Progression of dysprosody in Parkinson’s disease over time—a longitudinal study. Mov Disord 24:716–722CrossRefPubMed Skodda S, Rinsche H, Schlegel U (2009) Progression of dysprosody in Parkinson’s disease over time—a longitudinal study. Mov Disord 24:716–722CrossRefPubMed
13.
Zurück zum Zitat Midi I, Dogan M, Koseoglu M, Can G, Sehitoglu MA, Gunal DI (2008) Voice abnormalities and their relation with motor dysfunction in Parkinson’s disease. Acta Neurol Scand 117:26–34PubMed Midi I, Dogan M, Koseoglu M, Can G, Sehitoglu MA, Gunal DI (2008) Voice abnormalities and their relation with motor dysfunction in Parkinson’s disease. Acta Neurol Scand 117:26–34PubMed
14.
Zurück zum Zitat Rusz J, Cmejla R, Ruzickova H et al (2011) Acoustic assessment of voice and speech disorders in Parkinson’s disease through quick vocal test. Mov Disord 26(10):1951–1952CrossRefPubMed Rusz J, Cmejla R, Ruzickova H et al (2011) Acoustic assessment of voice and speech disorders in Parkinson’s disease through quick vocal test. Mov Disord 26(10):1951–1952CrossRefPubMed
15.
Zurück zum Zitat Goberman AM, Coelho C (2002) Acoustic analysis of Parkinsonian speech I: speech characteristics and l-Dopa therapy. NeuroRehabilitation 17:237–246PubMed Goberman AM, Coelho C (2002) Acoustic analysis of Parkinsonian speech I: speech characteristics and l-Dopa therapy. NeuroRehabilitation 17:237–246PubMed
16.
Zurück zum Zitat Robertson SJ, Thomson F (1987) Working with dysarthric clients: a practical guide to therapy for dysarthria. Communication Skill Builders, Tucson Robertson SJ, Thomson F (1987) Working with dysarthric clients: a practical guide to therapy for dysarthria. Communication Skill Builders, Tucson
17.
Zurück zum Zitat Fussi FC (2010) Profilo di valutazione della disartria. Adattamento italiano del test di Robertson, raccolta di dati normativi e linee di intervento. Omega Edizioni, Torino Fussi FC (2010) Profilo di valutazione della disartria. Adattamento italiano del test di Robertson, raccolta di dati normativi e linee di intervento. Omega Edizioni, Torino
19.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed
20.
Zurück zum Zitat Jacobson B, Johnson A, Grywalski C et al (1997) The Voice Handicap Index (VHI): development and validation. Am J Speech-Lang Pathol 6:66–69CrossRef Jacobson B, Johnson A, Grywalski C et al (1997) The Voice Handicap Index (VHI): development and validation. Am J Speech-Lang Pathol 6:66–69CrossRef
21.
Zurück zum Zitat Schindler A, Ottaviani F, Mozzanica F et al (2010) Cross-cultural adaptation and validation of the Voice Handicap Index Into Italian. J Voice 24:708–714CrossRefPubMed Schindler A, Ottaviani F, Mozzanica F et al (2010) Cross-cultural adaptation and validation of the Voice Handicap Index Into Italian. J Voice 24:708–714CrossRefPubMed
22.
Zurück zum Zitat Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153–164 Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153–164
23.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson’s disease. Arch Neurol 56:33–39CrossRefPubMed Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson’s disease. Arch Neurol 56:33–39CrossRefPubMed
24.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed
25.
Zurück zum Zitat Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2015) Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol 22(1):37–43CrossRefPubMed Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2015) Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol 22(1):37–43CrossRefPubMed
26.
Zurück zum Zitat Hays RD, Anderson R, Revicki D (1993) Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 2:441–449CrossRefPubMed Hays RD, Anderson R, Revicki D (1993) Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 2:441–449CrossRefPubMed
27.
Zurück zum Zitat Nunnally JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York Nunnally JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
28.
Zurück zum Zitat Fayers PM, Machin D (2000) Quality of life. Assessment, analysis and interpretation. Wiley, Chichester Fayers PM, Machin D (2000) Quality of life. Assessment, analysis and interpretation. Wiley, Chichester
29.
Zurück zum Zitat Scientific Advisory Committee of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11:193–205CrossRef Scientific Advisory Committee of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11:193–205CrossRef
30.
Zurück zum Zitat Skodda S, Flasskamp A, Schlegel U (2011) Instability of syllable repetition as a marker of disease progression in Parkinson’s disease: a longitudinal study. Mov Disord 26(1):59–64CrossRefPubMed Skodda S, Flasskamp A, Schlegel U (2011) Instability of syllable repetition as a marker of disease progression in Parkinson’s disease: a longitudinal study. Mov Disord 26(1):59–64CrossRefPubMed
31.
Zurück zum Zitat Gamboa J, Jimenez-Jimenez J, Nieto A et al (1997) Acoustic voice analysis in patients with Parkinson’s disease treated with dopaminergic drugs. J Voice 11:314–320CrossRefPubMed Gamboa J, Jimenez-Jimenez J, Nieto A et al (1997) Acoustic voice analysis in patients with Parkinson’s disease treated with dopaminergic drugs. J Voice 11:314–320CrossRefPubMed
32.
Zurück zum Zitat Skodda S, Grönheit W, Schlegel U (2012) Impairment of vowel articulation as a possible marker of disease progression in Parkinson’s disease. PLoS ONE 7:e32132CrossRefPubMedPubMedCentral Skodda S, Grönheit W, Schlegel U (2012) Impairment of vowel articulation as a possible marker of disease progression in Parkinson’s disease. PLoS ONE 7:e32132CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Skodda S, Visser W, Schlegel U (2011) Gender related patterns of dysprosody in Parkinson’s disease and correlation between speech variables and motor symptoms. J Voice 25:76–82CrossRefPubMed Skodda S, Visser W, Schlegel U (2011) Gender related patterns of dysprosody in Parkinson’s disease and correlation between speech variables and motor symptoms. J Voice 25:76–82CrossRefPubMed
34.
Zurück zum Zitat Skodda S, Visser W, Schlege U (2010) Short- and long-term dopaminergic effects on dysarthria in early Parkinson’s disease. J Neural Transm 117:197–205CrossRefPubMed Skodda S, Visser W, Schlege U (2010) Short- and long-term dopaminergic effects on dysarthria in early Parkinson’s disease. J Neural Transm 117:197–205CrossRefPubMed
35.
Zurück zum Zitat Rusz J, Mejla RC, Ruzickova H et al (2013) Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy. J Neural Transm 120:319–329CrossRefPubMed Rusz J, Mejla RC, Ruzickova H et al (2013) Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy. J Neural Transm 120:319–329CrossRefPubMed
36.
Zurück zum Zitat Tykalová T, Rusz J, Čmejla R, Klempíř J, Růžičková H, Roth J, Růžička (2015) Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm 122:1135–1142 Tykalová T, Rusz J, Čmejla R, Klempíř J, Růžičková H, Roth J, Růžička (2015) Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm 122:1135–1142
37.
Zurück zum Zitat Johansson L, Möller S, Olofsson K et al (2014) Word-level intelligibility after caudal zona incerta stimulation for Parkinson’s disease. Acta Neurol Scand 130:27–33CrossRefPubMed Johansson L, Möller S, Olofsson K et al (2014) Word-level intelligibility after caudal zona incerta stimulation for Parkinson’s disease. Acta Neurol Scand 130:27–33CrossRefPubMed
Metadaten
Titel
Assessment of voice and speech symptoms in early Parkinson’s disease by the Robertson dysarthria profile
verfasst von
Giovanni Defazio
Marta Guerrieri
Daniele Liuzzi
Angelo Fabio Gigante
Vincenzo di Nicola
Publikationsdatum
01.03.2016
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 3/2016
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-015-2422-8

Weitere Artikel der Ausgabe 3/2016

Neurological Sciences 3/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.